Literature DB >> 16371108

The CARI guidelines. Cardiovascular risk factors. Lipid-lowering therapy in patients with chronic kidney disease.

Rob Walker1.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16371108     DOI： 10.1111/j.1440-1797.2005.00507.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN： 1320-5358            Impact factor:   2.506


× No keyword cloud information.
  2 in total

Review 1.  Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Authors:  Giovanni F M Strippoli; Sankar D Navaneethan; David W Johnson; Vlado Perkovic; Fabio Pellegrini; Antonio Nicolucci; Jonathan C Craig
Journal:  BMJ       Date:  2008-02-25

2.  Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.

Authors:  Mahboob Rahman; Charles Baimbridge; Barry R Davis; Joshua I Barzilay; Jan N Basile; Mario A Henriquez; Anne Huml; Nelson Kopyt; Gail T Louis; Sara L Pressel; Clive Rosendorff; Sithiporn Sastrasinh; Carol Stanford
Journal:  Clin Nephrol       Date:  2013-10       Impact factor: 0.975
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.